Announcement of Share Issuance

LEI: 549300Q7EXQQH6KF7Z84

15 February 2021

RTW Venture Fund Limited

(the "Company")

Announcement of Share Issuance

Further to publication of the Company's 31 January 2021 net asset value, released on 15 February 2021, and taking into consideration interim performance of the Company's portfolio in February 2021, the Company confirms that it may issue new ordinary shares at a price of US$2.27 per new ordinary share, reflecting a 12.4 per cent. premium to the 31 January 2021 net asset value.

The Company intends to issue new ordinary shares on this basis until 17 February 2021. Investors wishing to participate in this issuance should reflect their interest to [email protected] and [email protected] at J.P. Morgan Cazenove.

For Further Enquiries

RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Senior Business Development Associate

J.P. Morgan Cazenove +44 (0)20 7742 4000William Simmonds

Jeremie Birnbaum (Corporate Finance)

James Bouverat (Sales)

Carrie Fox

Elysium Fund Management Limited +44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

Morgan Stanley Fund Services USA LLC +1 (914) 225 8885

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.